Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 10/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | F13A1 | P00488 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | TGM1 | P22735 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256948 | 0.85 | NR1H2 (0.40) | RORCNR1H2STSHTR6PDK4 | |
| SCHEMBL23538445 | 0.85 | RORC (0.37) | RORCNR1H2STSHTR6PDK4 | |
| SCHEMBL19168628 | 0.81 | RORC (0.38) | RORCNR1H2STSHTR6PDK4 | |
| SCHEMBL16422844 | 0.81 | STS (0.35) | RORCNR1H2STSHTR6PDK4 | |
| SCHEMBL29450192 | 0.78 | RORC (0.35) | RORCNR1H2STSHTR6PDK4 | |
| SCHEMBL19176058 | 0.78 | RORC (0.35) | RORCNR1H2STSHTR6PDK4 | |
| SCHEMBL23584522 | 0.78 | RORC (0.40) | RORCUSP30STSF13A1TGM2 | |
| SCHEMBL16434814 | 0.78 | RORC (0.33) | RORCSTSHTR6PDK4F13A1 | |
| SCHEMBL25322322 | 0.77 | NR1H2 (0.35) | RORCNR1H2STSHTR6PDK4 | |
| SCHEMBL21111699 | 0.76 | RORC (0.34) | RORCNR1H2STSHTR6PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006113458-A1 | HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | PRMT1, PRMT3, PRMT8 | RORC 1081/4885USP30 1388/4885NR1H2 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.